Key Highlights

  • Net loss per share was USD 0.15 against an estimate of a USD 0.1336 loss.
  • Net loss was USD 21.83 million, compared with USD 22.14 million.
  • Research and development expense was USD 17.46 million, compared with USD 17.44 million.
  • Cash and short-term investments were USD 35.45 million and USD 111.75 million.

ALX Oncology (NASDAQ:ALXO) reported a net loss of USD 21.83 million for the third quarter of 2026, compared with USD 22.14 million in the third quarter of 2025. The net loss per share was USD 0.15, compared with USD 0.41, against an estimate of a USD 0.1336 loss.

Operating Expenses

Research and development expense was USD 17.46 million, compared with USD 17.44 million. General and administrative expense was USD 5.48 million, compared with USD 5.09 million. Total operating expenses, which equal the loss from operations, were USD 22.95 million, compared with USD 22.53 million.

Interest income was USD 1.38 million, compared with USD 0.80 million, and interest expense was USD 0.23 million, compared with USD 0.41 million.

Nine-Month Results

For the nine months ended September 30, 2026, the net loss was USD 57.72 million, compared with USD 78.85 million, and the net loss per share was USD 0.45, compared with USD 1.48. Research and Development expense was USD 44.21 million, compared with USD 59.35 million, and general and administrative expense was USD 15.98 million, compared with USD 18.47 million. Total operating expenses were USD 59.95 million, compared with USD 81.00 million.

Balance Sheet

Cash and cash equivalents were USD 35.45 million at September 30, 2026, compared with USD 16.37 million at December 31, 2025. Short-term investments were USD 111.75 million, compared with USD 28.42 million. Prepaid expenses and other current Assets were USD 5.66 million, compared with USD 5.94 million, and total current assets were USD 152.87 million, compared with USD 50.73 million.

The company describes a clinical pipeline of two clinical-stage product candidates: the CD47 blocker evorpacept and ALX2004, an EGFR-targeted antibody-drug conjugate that entered a Phase 1 clinical trial in August 2025. Evorpacept is being evaluated in combination with trastuzumab and chemotherapy in patients with metastatic HER2-positive breast cancer in the Phase 2 ASPEN-09-Breast trial, and is also being studied in Clinical Trials with other targeted anti-cancer antibodies.

The filing states that the HSBC Loan agreement provides for an additional USD 20.0 million over two tranches, with USD 10.0 million available upon achievement of milestones related to the clinical development of evorpacept and ALX2004 and USD 10.0 million at the lender's sole discretion. The company also describes an at-the-market Equity offering program with sales agents under which it may sell shares of common stock having aggregate gross proceeds of up to USD 150.0 million.

Total assets were USD 154.67 million, compared with USD 59.05 million, and total liabilities were USD 28.82 million, compared with USD 33.07 million. The non-current term loan was USD 9.74 million, compared with USD 4.53 million, and total stockholders' equity was USD 125.85 million, compared with USD 25.98 million. The accumulated Deficit was USD 780.54 million, compared with USD 722.82 million.

ALX Oncology Q3 2026 Earnings: Key Takeaways

ALX Oncology reported a third quarter 2026 net loss of USD 21.83 million and a loss per share of USD 0.15. Cash and cash equivalents were USD 35.45 million at September 30, 2026.